Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient

被引：4
作者：
Kiykim, AA [1 ]
Ozer, C
Yildiz, A
Tiftik, N
Senli, M
Kelebek, E
Doruk, E
Akbay, E
机构：
[1] Univ Mersin, Fac Med, Dept Internal Med, Div Nephrol, TR-33079 Mersin, Turkey
[2] Univ Mersin, Fac Med, Dept Radiol, TR-33079 Mersin, Turkey
[3] Univ Mersin, Fac Med, Dept Internal Med, Div Hematol, TR-33079 Mersin, Turkey
[4] Univ Mersin, Fac Med, Dept Urol, TR-33079 Mersin, Turkey
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2004年 / 19卷 / 10期
关键词：
haemolytic-uraemic syndrome; tacrolimus; transplant renal artery thrombosis;
D O I：
10.1093/ndt/gfh375
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：2653 / 2656
页数：4
相关论文
共 10 条
[1]   Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus [J].
Abraham, KA ;
Little, MA ;
Dorman, AM ;
Walshe, JJ .
TRANSPLANT INTERNATIONAL, 2000, 13 (06) :443-447
[2]   Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Blom, HJ ;
Sweep, FCGJ ;
Demacker, PNM ;
Hilbrands, LB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1880-1888
[3]   Cyclosporine-related hemolytic-uremic syndrome in kidney graft recipients: Clinical and histomorphologic evaluation [J].
Bren, AF ;
Kandus, A ;
Buturovic, J ;
Koselj, M ;
Pavlovcic, SK ;
Ponikvar, R ;
Kovac, D ;
Lindic, J ;
Vizjak, A ;
Ferluga, D .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1201-1203
[4]   Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: Potential implications in transplant arteriopathy [J].
Freudenberger, R ;
Alexis, J ;
Gass, A ;
Fuster, V ;
Badimon, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (12) :1228-1231
[5]   Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities [J].
Furlong, T ;
Storb, R ;
Anasetti, C ;
Appelbaum, FR ;
Deeg, HJ ;
Doney, K ;
Martin, P ;
Sullivan, K ;
Witherspoon, R ;
Nash, RA .
BONE MARROW TRANSPLANTATION, 2000, 26 (09) :985-991
[6]  
Lin CC, 2003, J NEPHROL, V16, P580
[7]   Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura [J].
Nabhan, C ;
Kwaan, HC .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (01) :177-+
[8]   Overview of side effects of immunosuppressive therapy [J].
Paul, LC .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (03) :2089-2091
[9]   Thrombotic microangiopathy after renal transplantation in the United States [J].
Reynolds, JC ;
Agodoa, LY ;
Yuan, CM ;
Abbott, KC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (05) :1058-1068
[10]   Cyclosporin conversion to CellCept in a cadaveric renal allograft recipient with hemolytic uremic syndrome [J].
Said, T ;
Al-Mousawi, M ;
Samhan, M ;
Lao, M .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (08) :3295-3297
1